Open AccessThe use of a polyvalent bacterial lysate in a complex therapy of chronic urticaria
Author(s) -
Е. В. Сорокина,
Н. Г. Сивакова,
Elina Akhmatova,
Н. Н. Митрофанова,
С. А. Сходова,
Н. К. Ахматова
Publication year - 2019
Publication title -
žurnal mikrobiologii, èpidemiologii i immunobiologii
Language(s) - English
Resource type - Journals
eISSN - 2686-7613
pISSN - 0372-9311
DOI - 10.36233/0372-9311-2019-5-34-39
Subject(s) - medicine , tlr2 , immunology , tlr4 , innate immune system , antigen , flow cytometry , toll like receptor , chronic urticaria , tlr9 , immune system , biology , gene expression , dna methylation , gene , biochemistry
The aim of the study was to study trigger factors in chronic urticaria, peculiarities in the expression of Toll-like receptors, clinical and immunological efficacy of microbial antigens in patients with chronic urticaria. Materials and methods . Patients with chronic urticaria (134 patients). A study of the expression of TLR2, TLR3, TLR4, TLR9 on blood cells using flow cytometry. 62 patients received polyvalent bacterial lysate against baseline therapy per os, 72 patients received monotherapy with basic drugs. Results . In patients with bacterial infection, high levels of TLR2, TLR4 expression were detected. In the presence of viral infections, high TLR3 expression values were observed. The use of PBL contributed to an increase in the number of patients with clinical remission, decreased urticaria activity, led to a correction in TLR2 and TLR4, and decreased the level of total IgE. Conclusion . Inclusion in the complex of therapeutic and prophylactic measures in patients with urticaria of a chronic drug based on microbial antigens (polyvalent bacterial lysate) contributes to the increase of clinical effectiveness and activation of the links of innate immunity.